The Takeda Pharmaceutical Company’s headquarters in Chuo-ku, Osaka, Japan. Credit: J o / commons.wikimedia.org.

Takeda has reported a 12.8% increase in its reported revenue to $29.96bn (Y4,027bn) during the fiscal year 2022 (FY2022) compared to that reported in FY2021.

At a constant exchange rate (CER), the company’s core revenue grew by 3.5% compared to the previous year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In the FY2022 ending 31 March 2023, the company also reported a 6.4% rise in its operating profit to $3.65bn (Y490.5bn) compared to 2021.

Reported earnings per share (EPS) grew by 38.8% to $1.5bn (Y204bn) and net profit for FY2021 increased by 37.8% to $2.36bn (Y317bn).

The same fiscal year recorded a 13% decline to $7.27bn (Y977.2bn) in operating cash flow.

The company has provided commercial updates across its five key business areas: gastroenterology (GI), rare diseases, plasma-derived therapy (PDT) immunology, oncology and neuroscience.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Its GI business reported an 8.7% increase in revenue to $8.145bn (Y1,094.5bn) on a CER basis.

Entyvio, for ulcerative colitis (UC) and Crohn’s disease (CD), steered the growth in the revenue of this business.

Rare diseases reported revenue growth of 4.8% to $5.38bn (Y723.4bn) and PDT immunology reported growth of 15.3% to $5.048bn (Y678.4bn), both on a CER basis.

Oncology reported a 14.4% decline in reported revenue on a CER basis to $3.26bn (Y438.7bn).

In neuroscience, reported revenue rose by 12.1% to $4.75bn (Y637.7bn) on a CER basis.

Takeda chief financial officer Costa Saroukos stated: “I’m pleased to report that Takeda delivered or exceeded management guidance in FY2022 and booked a record core operating profit of almost Y1.2tn.

“Our topline and profit performance was driven by our growth and launch products, which grew 19% at a constant exchange rate.

“Strong financial discipline and free cash flow have enabled us to deleverage rapidly while investing in growth.”

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now